Novel Approaches to the Treatment of Alzheimer’s Disease: Advances in Behavioral Biology, cartea 36
Editat de E. Meyeren Limba Engleză Paperback – 25 noi 2012
Din seria Advances in Behavioral Biology
- 5% Preț: 368.00 lei
- Preț: 401.79 lei
- Preț: 406.63 lei
- 15% Preț: 649.54 lei
- Preț: 387.20 lei
- Preț: 405.28 lei
- Preț: 381.43 lei
- 5% Preț: 378.07 lei
- 5% Preț: 372.76 lei
- 5% Preț: 724.50 lei
- 5% Preț: 668.50 lei
- 5% Preț: 378.97 lei
- 15% Preț: 672.62 lei
- Preț: 385.08 lei
- 15% Preț: 673.27 lei
- Preț: 407.39 lei
- 5% Preț: 713.74 lei
- 5% Preț: 716.84 lei
- 5% Preț: 372.59 lei
- 15% Preț: 680.47 lei
- 15% Preț: 687.19 lei
- 15% Preț: 596.01 lei
- Preț: 421.05 lei
- 15% Preț: 661.65 lei
- 15% Preț: 663.27 lei
- 5% Preț: 402.17 lei
- 5% Preț: 369.29 lei
- Preț: 409.30 lei
- 15% Preț: 660.18 lei
- Preț: 386.00 lei
- 15% Preț: 646.62 lei
- Preț: 403.15 lei
- Preț: 406.63 lei
- 5% Preț: 756.15 lei
- 5% Preț: 406.57 lei
- 15% Preț: 638.11 lei
- 5% Preț: 389.93 lei
- 5% Preț: 392.13 lei
- 5% Preț: 719.74 lei
- Preț: 389.49 lei
- 5% Preț: 2147.36 lei
- 5% Preț: 1424.68 lei
- 5% Preț: 1430.35 lei
- 5% Preț: 2124.15 lei
Preț: 397.59 lei
Nou
Puncte Express: 596
Preț estimativ în valută:
76.10€ • 78.42$ • 64.25£
76.10€ • 78.42$ • 64.25£
Carte tipărită la comandă
Livrare economică 04-18 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781468457292
ISBN-10: 1468457292
Pagini: 404
Ilustrații: XIV, 386 p. 137 illus.
Dimensiuni: 170 x 244 x 21 mm
Greutate: 0.64 kg
Ediția:Softcover reprint of the original 1st ed. 1989
Editura: Springer Us
Colecția Springer
Seria Advances in Behavioral Biology
Locul publicării:New York, NY, United States
ISBN-10: 1468457292
Pagini: 404
Ilustrații: XIV, 386 p. 137 illus.
Dimensiuni: 170 x 244 x 21 mm
Greutate: 0.64 kg
Ediția:Softcover reprint of the original 1st ed. 1989
Editura: Springer Us
Colecția Springer
Seria Advances in Behavioral Biology
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
Section I. Drugs that Act at Cholinergic Receptors.- A Functionalized Congener Approach to Muscarinic Ligands.- AF102B: A Novel M1 Agonist as a Rational Treatment Strategy in Alzheimer’s Disease.- Muscarinic Receptors, Phosphoinositide Hydrolysis and Neuronal Plasticity in the Hippocampus.- Effects of Cholinergic Drugs on Extracellular Levels of Acetylcholine and Choline in Rat Cortex, Hippocampus and Striatum Studied byu Brain Dialysis.- Delayed Matching-to-Sample in Monkeys as a Model for Learning and Memory Deficits: Role of Brain Nicotinic Receptors.- Muscarinic and Nicotinic Receptors in Alzheimer’s Disease: Rationale for Cholinergic Drug Treatment.- Section II. CNS-Active Neurotrophic Factors.- Potential Pharmacological Use of Neurotrophic Factors in the Treatment of Neurodegenerative Diseases.- The Use of Reaggregating Cell Cultures and Immortalized Central Nervous System Cells to Study Cholinergic Trophic Mechanisms.- Approaches to Gene Therapy in the CNS: Intracerebral Grafting of Fibroblasts Genetically Modified to Secrete Nerve Growth Factor.- Exogenous Nerve Growth Factor Stimulates Choline Acetyltransferase Activity in Basal Forebrain of Axotomized and Aged Rats.- Neuronotrophic Factors, Gangliosides and Their Interaction: Implications in the Regulation of Nervous System Plasticity.- Suppression of Active Neuronal Death by Immune Interferon.- Basic Fibroblast Growth Factor, an Example of a Multifunctional Trophic Factor with Neurotrophic Activity.- Growth Factor and Lymphokine Effects on Brain Cholinergic Systems.- Metabolic Support of Neural Plasticity: Implications for the Treatment of Alzheimers Disease.- Section III. Additional Novel Treatment Strategies: Improved Brain Delivery, Hormones, and Immunology.- Brain-Enhanced Delivery of Anti-DementiaDrugs.- Development of a Pyrrolidinone Derivative (Cyclic GABA)for Modulating Brain Glutamate Transmission.- A Brain-Enhanced Chemical Delivery System for Gonadal Steroids: Implications for Neurodegenerative Diseases.- Immunologic Approach to Therapy in Alzheimer’s Disease.- The Influence of ACTH 4–9 Analog upon Avoidance Learning in Normal and Brain Damaged Rats.- Section IV. Models for Drug-Development: Cholinergic Hypofunction.- Transneuronal Neurochemical and Neuropathological Changes Induced by Nucleus Basalis Lesions: A Possible Degenerative Mechanism in Alzheimer’s Disease.- Presynaptic Markers of Cholinergic Function in Cortex Following Ibotenic Acid Lesion of the Basal Forebrain.- Cholinergic-Neuropeptide Y Interactions in the Rat Cerebralcortex: Towards a Model for the Trans-synapticEffects of Cholinergic Transmission.- The Effects of Nucleus Basalis Lesions in the Rat on One Way Passive and Active Avoidance, Two Way Avoidance and Lashly III Maze Learning: An Animal Model for SDAT.- Section V. Models for Drug Development: Other Neurochemical and Behavioral Changes.- NMDA Receptors, Aging and Alzheimer’s Disease.- An Excitotoxic Model of Alzheimer’s Disease: NMDA Lesions and Initial Neural Grafting Results.- Excitotoxin Mediated Neuronal Loss and the Regulation of Excitatory Amino Acid Release in the Aging Brain.- EEG Power Spectra and Brain Function.- Postmortem Stability of RNA Metabolism in Human Brain: Studies of the Nondemented Conrol and Alzheimer’s Disease Cases.- A Model System Demonstrating Parallels in Animal and Human Aging: Extension to Alzheimer’s Disease.- Computer-Simulated Everyday Memory Testing for Clinical Trials in Memory Disorders of Aging.